Louis Guize

Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest), Lutetia Parisorum, Île-de-France, France

Are you Louis Guize?

Claim your profile

Publications (4)5.65 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the cardiovascular prognosis of 1845 Diabetic Patients (DP) and 6443 Non-Diabetic Patients (NDP) in secondary prevention. Patients were recruited prospectively if they had had a previous history of ischemic stroke or acute coronary syndrome (ACS) i.e. Myocardial Infarction (MI) or Unstable Angina (UA) within a period of five years preceding inclusion. For each patient, the number of hospitalizations and vital status were recorded each month over a 6-month period (mean follow-up: 4.8 months). 306 patients (9.5/100--person years; 95% CI, 8.5 to 10.6) had undergone at least one subsequent event (hospitalization for ACS, ischemic stroke, or cardiovascular death). A majority of these events were non-fatal ACS (n=248). The cumulative incidence rate of subsequent events was higher in DP: 12.6/100- person years (10.0 to 15.2) than in NDP: 8.6/100--person years (7.5 to 9.8). DP were significantly at higher risk of subsequent cardiovascular events (OR: 1.34; P=0.025) after adjustment for confounding factors. 93% of coronary DP and NDP underwent a recurrent event affecting the same location. When the index episode was a stroke, 71% of DP had a subsequent stroke vs. 47% of NDP. in secondary prevention, the risk of mortality and subsequent vascular events is independently higher in French DP than in NDP. The locations affected by each type of subsequent cardiovascular event seemed correlated to the baseline diagnosis, whatever the diabetic status, even when the frequency of subsequent strokes increased (not significantly) in DP when compared to NDP.
    Diabetes & Metabolism 12/2006; 32(5 Pt 1):460-6. · 2.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the Prevenir III study was to assess, in secondary prevention, the risk after 6 months of subsequent coronary and cerebrovascular events in a population of patients in private practice. A prospective observational survey, including patients diagnosed with previous myocardial infarction, unstable angina or stroke, was carried out by French general practitioners and cardiologists. 9556 patients were selected by 3746 physicians representative of French physicians. The medical records of 8288 were analyzed. After a 6-month follow-up, 116 patients (1.4%) had been hospitalized for coronary or cerebrovascular event i.e. cumulative incidence 3.6 per 100 person-years (95% CI 2.9-4.2). The rate of coronary events was 0.9% and the cumulative incidence 2.3% person-years (95% CI 1.8-2.8), the event rate of stroke was 0.5% and the cumulative incidence 1.3 person-years (95% CI 0.9-1.7) and all-cause mortality was 1.2% i.e. 3.1 per 100 person-years (95% CI 2.5-3.7). Patients treated with statins and antiplatelet agents, or both, were less likely to undergo subsequent events than patients not receiving statins or antiplatelet agents. All-cause mortality rate decreased dramatically (Hazard Ratio 0.4 95% CI 0.2-0.7 after adjustment for age, sex, diagnosis at inclusion, time elapsed since the index event, cardiovascular and non cardiovascular history, betablockers, angiotensin-converting enzyme inhibitors and cardiovascular risk factors) in patients treated with a combination of statins and antiplatelet agents when compared to patients treated with neither statins nor antiplatelet agents. Our survey enabled a better understanding of the prognosis at 6 months in a large sample of coronary and cerebrovascular patients. We observed the beneficial impact of the combination of statins and antiplatelet agents in cardiovascular secondary prevention.
    Cardiovascular Drugs and Therapy 03/2006; 20(1):55-61. · 2.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: AIM OF THE SURVEY: The aim of the PREVENIR III study was to assess, in secondary prevention, the risk of subsequent coronary and cerebrovascular events at six months in a population of patients in private practice. This was a prospective observational survey (6-month follow-up), including patients diagnosed with previous myocardial infarction, unstable angina or ischemic stroke, carried out by French general practitioners and cardiologists in private practice. 8288 patients were selected by 3746 physicians (2961 general practitioners and 785 cardiologists) representative of French metropolitan physicians in private practice. In this analysis the medical records of 6859 coronary patients were analyzed. After a 6-month follow-up, 84 patients had been hospitalized for a subsequent coronary or cerebrovascular event (1.2%) i.e. cumulative incidence 3.1 event per 100 person-years (95% CI 2.4-3.8). In the coronary population 77.4% of the subsequent vascular events were coronary events and 22.6% were cerebrovascular events. The event rate of coronary events was 0.9% and the cumulative incidence 2.3 event per 100 person-years (95% CI 1.8-2.8), the risk of secondary ischemic stroke was 0.3% and the cumulative incidence 0.7 event per 100 person-years (95% CI 0.4-1.0), and the all-cause mortality rate was 1.0% and the cumulative incidence 2.5 event per 100 person-years (95% CI 1.9-3.1). 61.0% of total death was cardiovascular deaths. Multivariate analysis showed that older age, recent index event, three vessel disease were more likely to undergo recurrent events. Our survey enabled a better understanding of the prognosis at six months for a large sample of coronary patients recruited in private practice medicine. For coronary patients treated in private practice the risk of subsequent events and total mortality is far from insignificant.
    Annales de Cardiologie et d Angéiologie 01/2006; 54 Suppl 1:S2-9. · 0.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the PREVENIR III study was to assess, in secondary prevention, the risk after six months of subsequent coronary and cerebrovascular events. A prospective observational survey, including patients diagnosed with previous myocardial infarction, unstable angina or ischemic stroke, was carried out by French general practitioners and cardiologists. 9556 patients were selected by 3746 physicians representative of French physicians. The medical records of 6859 patients with previous unstable angina or myocardial infarction were analyzed. After a 6-month follow-up, 84 patients (1.2%) had been hospitalized for coronary or cerebrovascular event i.e. cumulative incidence 3.1 per 100 person-years (95% CI 2.4-3.8) and 67 patients died (1.0%) i.e. 2.5 per 100 person-years (95% CI 1.9-3.1). Patients treated with statins and antiplatelet agents were less likely to undergo subsequent vascular events (relative risk: 0.35; 95% CI 0.20-0.61) than patients not receiving statins or antiplatelet agents. All-cause mortality rate decreased dramatically (relative risk: 0.32; 95% CI 0.16-0.65) in patients treated with a combination of statins and antiplatelet agents when compared to patients treated with neither statins nor antiplatelet agents. This work enabled a better understanding of the prognosis at six months in a large sample of coronary patients. We observed the beneficial impact of the combination of statins and antiplatelet agents in secondary prevention.
    Annales de Cardiologie et d Angéiologie 01/2006; 54 Suppl 1:S10-6. · 0.30 Impact Factor

Publication Stats

15 Citations
5.65 Total Impact Points

Institutions

  • 2006
    • Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest)
      • Département de Cardiologie
      Lutetia Parisorum, Île-de-France, France
    • Centre Hospitalier Universitaire de Toulouse
      Tolosa de Llenguadoc, Midi-Pyrénées, France